Continuous Glucose Monitoring Improves Blood Glucose Control in Type 2 Diabetes

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 4, 2026.

via HealthDay

MONDAY, May 4, 2026 -- Real-time continuous glucose monitoring (CGM) improves blood glucose management in adults with type 2 diabetes managed with basal insulin, according to a study published online April 23 in The Lancet Diabetes & Endocrinology.

Emma G. Wilmot, Ph.D., from the University of Nottingham School of Medicine in the United Kingdom, and colleagues conducted an open-label, randomized controlled trial involving adults with type 2 diabetes managed with basal insulin and sodium-glucose transport protein 2 inhibitors or glucagon-like peptide (GLP)-1 receptor agonists or dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists with hemoglobin A1c (HbA1c) of 7.5 to 11.0 percent. Participants were randomly assigned to CGM (intervention) or continuation of self-monitoring of blood glucose (control; 198 and 105 participants, respectively) across two phases: weeks 1 to 16 (self-management with basal insulin self-titration) and weeks 17 to 32 (additional therapies could be initiated in line with national guidance).

The researchers found that baseline HbA1c was 8.8 and 8.8 percent in the CGM and control groups, decreasing to 8.0 and 8.7 percent, respectively, at week 16 (adjusted difference, −0.6) and decreasing further to 7.8 and 8.3 percent, respectively, at week 32 (adjusted difference, −0.5). The incidence of non-device-related adverse events was similar in both groups; the control group had two instances of severe hypoglycemia.

"The FreeDM2 trial highlights how CGM can help those with basal insulin-treated type 2 diabetes," Wilmot said in a statement. "Individuals I supported during the trial told me that the use of CGM gave them new insights into their diabetes management, with many describing it as 'life changing.'"

Several authors disclosed ties to biopharmaceutical companies, including Abbott Diabetes Care, which funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-05 02:23

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords